Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

16.71USD
20 Feb 2018
Change (% chg)

$1.16 (+7.46%)
Prev Close
$15.55
Open
$15.67
Day's High
$16.91
Day's Low
$15.67
Volume
30,054
Avg. Vol
13,998
52-wk High
$16.91
52-wk Low
$2.77

Select another date:

Fri, Dec 22 2017

BRIEF-GTX Inc Files For Mixed Shelf Offering Of Up To $150 Mln

* GTX INC FILES FOR MIXED SHELF OFFERING OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2kHuojK) Further company coverage:

BRIEF-GTX reports qtrly ‍loss per share $0.53​

* GTX provides corporate update and reports third quarter 2017 financial results

BRIEF-GTX Inc files for offering of up to 8.8 million shares of common stock

* GTX Inc files for offering of up to 8.8 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2zotwFH) Further company coverage:

BRIEF-Amzak Health Investors Llc reports 6.15 pct passive stake in GTX as of Sept 29

* Amzak Health Investors Llc reports 6.15 percent passive stake in GTX Inc as of September 29 - SEC Filing‍​ Source text: (http://bit.ly/2zdLcEN) Further company coverage:

BRIEF-Aisling capital IV LP reports 6.2 pct passive stake in GTX as of Sept 29

* Aisling Capital IV LP reports 6.2 percent passive stake in GTX Inc as of Sept 29 - SEC Filing Source text: (http://bit.ly/2xW9yVO) Further company coverage:

BRIEF-Gtx announces closing of $48.5 million private placement

* Gtx announces closing of $48.5 million private placement Source text for Eikon: Further company coverage:

BRIEF-GTx announces $48.5 million private placement

* GTx - ‍entered into agreement for sale of its common stock & warrants to purchase common stock in private placement with gross proceeds of $48.5 million

BRIEF-GTx announces positive results from enobosarm Phase 2 proof-of-concept clinical trial

* GTx announces positive results from enobosarm phase 2 proof-of-concept clinical trial in women with stress urinary incontinence

Select another date: